myrbetriq Drug Patent Profile
✉ Email this page to a colleague
When do Myrbetriq patents expire, and what generic alternatives are available?
Myrbetriq is a drug marketed by Apgdi and is included in two NDAs. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and eleven patent family members in thirty countries.
The generic ingredient in MYRBETRIQ is mirabegron. There are nineteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the mirabegron profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Myrbetriq
A generic version of myrbetriq was approved as mirabegron by LUPIN LTD on September 28th, 2022.
Summary for myrbetriq
International Patents: | 111 |
US Patents: | 7 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 74 |
Clinical Trials: | 48 |
Patent Applications: | 57 |
Drug Prices: | Drug price information for myrbetriq |
Drug Sales Revenues: | Drug sales revenues for myrbetriq |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for myrbetriq |
What excipients (inactive ingredients) are in myrbetriq? | myrbetriq excipients list |
DailyMed Link: | myrbetriq at DailyMed |
Recent Clinical Trials for myrbetriq
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The University of Texas Medical Branch, Galveston | Early Phase 1 |
University of California, San Diego | Phase 1 |
Shachi Tyagi | Phase 4 |
Pharmacology for myrbetriq
Anatomical Therapeutic Chemical (ATC) Classes for myrbetriq
Paragraph IV (Patent) Challenges for MYRBETRIQ
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
MYRBETRIQ | Extended-release Tablets | mirabegron | 50 mg | 202611 | 6 | 2016-06-28 |
US Patents and Regulatory Information for myrbetriq
myrbetriq is protected by seven US patents and two FDA Regulatory Exclusivities.
Patents protecting myrbetriq
Pharmaceutical composition for modified release
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
.alpha.-form or .beta.-form crystal of acetanilide derivative
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
.alpha.-form or .beta.-form crystal of acetanilide derivative
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pharmaceutical composition for treating overactive bladder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting myrbetriq
TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 3 YEARS AND OLDER AND WEIGHING 35 KILOGRAMS OR MORE
Exclusivity Expiration: ⤷ Sign Up
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-002 | Jun 28, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-002 | Jun 28, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for myrbetriq
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-002 | Jun 28, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-002 | Jun 28, 2012 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for myrbetriq
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Astellas Pharma Europe B.V. | Betmiga | mirabegron | EMEA/H/C/002388 Symptomatic treatment of urgency.Increased micturition frequency and / or urgency incontinence as may occur in adult patients with overactive-bladder syndrome. |
Authorised | no | no | no | 2012-12-20 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for myrbetriq
When does loss-of-exclusivity occur for myrbetriq?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Canada
Patent: 04298
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0121078
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 13670
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 16021
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 16021
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 2009057685
Estimated Expiration: ⤷ Sign Up
Patent: 63170
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 16021
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 16021
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 16021
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 93525
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering myrbetriq around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Africa | 201102406 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE | ⤷ Sign Up |
South Korea | 100967070 | ⤷ Sign Up | |
Germany | 69823858 | ⤷ Sign Up | |
Hungary | 226456 | SUSTAINED-RELEASE HYDROGEL PREPARATION | ⤷ Sign Up |
Norway | 20042227 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for myrbetriq
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1559427 | 300599 | Netherlands | ⤷ Sign Up | PRODUCT NAME: MIRABEGRON EN ZOUTEN ERVAN; REGISTRATION NO/DATE: EU/1/12/809/001-014 20130107 |
1559427 | 1390028-7 | Sweden | ⤷ Sign Up | PRODUCT NAME: MIRABEGRON ELLER ETT SALT DAERAV; REG. NO/DATE: EU/1/12/809/001 20121220 |
1559427 | 92218 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: MIRABEGRON OU UN DE SES SELS |
1559427 | 33/2013 | Austria | ⤷ Sign Up | PRODUCT NAME: MIRABEGRON ODER DESSEN SALZE; REGISTRATION NO/DATE: EU/1/12/809/001-014 20121220 |
1028111 | CA 2013 00029 | Denmark | ⤷ Sign Up | PRODUCT NAME: MIRABEGRON OR SALTS THEREOF; REG. NO/DATE: EU/1/12/809/001-014 20121220 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |